zurück

Relugolix / estradiol / norethisterone acetate (uterine fibroids)

Subject:

  • Active Substance: Relugolix / estradiol / norethisterone acetate
  • Name: Ryeqo®
  • Therapeutic area: Uterine fibroids
  • Pharmaceutical company: Gedeon Richter Pharma GmbH

Time table:

  • Start: 01.09.2021
  • Final decision by G-BA: 17.02.2022

Final decision:

  • Patients for whom watchful waiting is the best suited patient-individual therapy:
    - Hint for a considerable additional benefit
  • Patients for whom watchful waiting is not the best suited patient-individual therapy:
    - No additional benefit proved